SEC Filing Summary: Stellar Biotechnologies Inc.
Business Context and Reporting Period
This Form 6-K was filed by Stellar Biotechnologies Inc. on October 17, 2013, for the month of September 2013. The filing serves as a report of a foreign issuer under Rule 13a-16 and 15d-16 of the Securities Exchange Act of 1934. The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided text does not contain specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The filing references "Interim Financial Statements for the period ended May 31, 2013" and "Management Discussion and Analysis" as Exhibits 99.1 and 99.2, but the content of these exhibits is not included in the input text.
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or unusual items. These details are likely contained within the referenced Management Discussion and Analysis exhibit, which is not present in the source text.
Investor Verification Checklist
- Verify the actual financial performance by reviewing Exhibit 99.1 (Interim Financial Statements for the period ended May 31, 2013).
- Review Exhibit 99.2 (Management Discussion and Analysis) for operational updates and risk factors.
- Confirm the discrepancy between the company name in the metadata request ("Edesa Biotech, Inc.") and the registrant name in the filing ("Stellar Biotechnologies Inc.").
- Note that the financial statements referenced cover a period ending May 31, 2013, which precedes the filing date of October 2013.